Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
67.57
-3.00 (-4.25%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 67.18 - 70.89
52 week 49.96 - 140.00
Open 69.96
Vol / Avg. 1.24M/908,133.00
Mkt cap 5.52B
P/E     -
Div/yield     -
EPS -4.03
Shares 85.36M
Beta 2.47
Inst. own 85%
Aug 4, 2016
Q2 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 7, 2016
Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference - 11:00AM EDT - Add to calendar
May 12, 2016
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 10, 2016
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting
May 4, 2016
Alnylam Pharmaceuticals Inc at Deutsche Bank Health Care Conference
May 2, 2016
Q1 2016 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
May 2, 2016
Q1 2016 Alnylam Pharmaceuticals Inc Earnings Release
Apr 29, 2016
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Apr 20, 2016
Alnylam Pharmaceuticals Inc Conference Call to discuss 18-Month data from its ongoing Phase 2 open-label extension
Apr 13, 2016
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1401.96% -705.83%
Operating margin -1498.00% -720.27%
EBITD margin - -673.91%
Return on average assets -30.56% -23.52%
Return on average equity -33.66% -26.36%
Employees 369 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
David-Alexandre Gros M.D. Senior Vice President, Chief Business Officer
Age: 43
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 41
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters
Marsha H. Fanucci Independent Director
Age: 62
Bio & Compensation  - Reuters